Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Income from Continuing Operations (2016 - 2025)

Marimed (MRMD) has disclosed Income from Continuing Operations for 15 consecutive years, with 4641000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 43.84% to 4641000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 14272000.0 through Dec 2025, down 17.13% year-over-year, with the annual reading at 14456000.0 for FY2025, 16.3% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 4641000.0 at Marimed, down from 2941000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 7589000.0 in Q2 2021, with the low at 10128000.0 in Q4 2023.
  • Average Income from Continuing Operations over 5 years is 1061050.0, with a median of 1130000.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations soared 764.98% in 2021, then crashed 319.5% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 6398000.0 in 2021, then skyrocketed by 174.23% to 4749000.0 in 2022, then tumbled by 313.27% to 10128000.0 in 2023, then grew by 18.4% to 8264000.0 in 2024, then surged by 43.84% to 4641000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 4641000.0, 2941000.0, and 1270000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.